WeVote
Log In

Bill

Bill

HB 1076

Pharmaceutical Substance Manufacturing Grant Fund; created.

2026 Regular Session Introduced by Katrina Callsen and 1 co-sponsor

Virginia establishes a pharmaceutical manufacturing grant fund to subsidize drug production facilities, creating jobs and economic development while committing ongoing state resources to competitive grants.

Approved by Governor-Chapter 808 (effective 7/1/2026)
0
WeVote Research Nonpartisan
Bill Summary · HB 1076

Legislative bill overview

HB 1076 establishes a new grant fund in Virginia to support pharmaceutical substance manufacturing facilities and related operations. The bill allocates state resources to incentivize pharmaceutical production within the state, likely through competitive grants to companies meeting specified criteria.

Why is this important

Pharmaceutical manufacturing represents significant economic development potential, creating high-wage jobs and reducing supply chain vulnerabilities for essential medicines. Virginia's investment in this sector could position the state as a regional hub for drug production while generating tax revenue and employment in targeted communities.

Potential points of contention

  • Fiscal commitment: Establishing a new grant fund requires ongoing state budget allocation; the bill's funding mechanism and amount are not detailed in available information, raising questions about sustainability and opportunity costs
  • Industry selectivity: Grant programs inherently favor certain companies or manufacturing types, creating fairness concerns about which applicants receive public subsidies and potential competitive disadvantages for non-recipients
  • Economic return uncertainty: Manufacturing incentive grants carry execution risk—facilities may relocate after receiving funds, fail to meet job creation targets, or deliver lower-than-projected economic benefits to justify the public investment

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.